Metabolism of digoxin and digoxigenin digitoxosides in rat liver microsomes: Involvement of cytochrome P4503A

Xenobiotica

Volumn 29, Issue 2, 1999, Pages 171-185

  Salphati, Laurent ^a   Benet, Leslie Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYTOCHROME P450; DIGOXIGENIN; DIGOXIGENIN DIGITOXOSIDE; DIGOXIN; ETHINYLESTRADIOL; GESTODENE; KETOCONAZOLE; TROLEANDOMYCIN;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DECOMPOSITION; DRUG METABOLISM; ENZYME INHIBITION; ENZYME MECHANISM; FEMALE; LIVER MICROSOME; MALE; MICHAELIS CONSTANT; NONHUMAN; OXIDATION; RAT;

ANIMALIA; STAPHYLOCOCCUS PHAGE 3A;

EID: 0032910725     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982599238722     Document Type: Article

References (26)

1. ANTMAN, E. M. and SMITH, T. W., 1985, Digitalis toxicity. Annual Review of Medicine, 36, 357-367.
2. CHANG, T. K., GONZALEZ, F. J. and WAXMAN, D. J., 1994, Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Archives of Biochemistry and Biophysics, 311, 437-442.
3. CORREIA, M. A., 1995, Rat and human liver cytochromes P450. In P. R. Ortiz de Montellano (ed.), Cytochrome P450: Structure, Mechanism, and Biochemistry (New York: Plenum), pp. 607-630.
4. GAULT, H., KALRA, J., AHMED, M., KEPKAY, D. and BARROWMAN, J., 1980, Influence of gastric pH on digoxin biotransformation. I. Intragastric hydrolysis. Clinical Pharmacology and Therapeutics, 27, 16-21.
5. GAULT, H., KALRA, J., AHMED, M., KEPKAY, D., LONGERICH, L. and BARROWMAN, J., 1981, Influence of gastric pH on digoxin biotransformation. II. Extractable urinary metabolites. Clinical Pharmacology and Therapeutics, 29, 181-190.
6. GUENGERICH, F. P., 1988, Oxidation of 17α-ethynylestradiol by human liver cytochrome P-450. Molecular Pharmacology, 33, 500-508.
7. GUENGERICH, F. P., 1989, Analysis and characterization of enzymes. In A. W. Hayes (ed.), Principles and Methods of Toxicology (New York: Raven), pp. 777-814.
8. GUENGERICH, F. P., 1990, Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chemical Research in Toxicology, 3, 363-371.
9. HARRISON, L. I. and GIBALDI, M., 1976, Pharmacokinetics of digoxin in the rat. Drug Metabolism and Disposition, 4, 88-93.
10. HEDMAN, A. and MEIJER, D. K., 1998, Stereoselective inhibition by the diastereomers quinidine and quinine of uptake of cardiac glycosides into isolated rat hepatocytes. Journal of Pharmaceutical Sciences, 87, 457-461.
11. HELLER, M., 1990, Cardiac glycosides. New/old ideas about old drugs. Biochemical Pharmacology, 40, 919-925.
12. KELLY, R. A. and SMITH, T. W., 1996, Pharmacological treatment of heart failure. In J. G. Hardman and L. E. Limbird (eds), Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th edn (New York: McGraw-Hill), pp. 809-838.
13. KLAASSEN, C. D., 1974, Effect of microsomal enzyme inducers on the biliary excretion of cardiac glycosides. Journal of Pharmacology and Experimental Therapeutics, 191, 201-211.
14. LACARELLE, B., RAHMANI, R., DE SOUSA, G., DURAND, A., PLACIDI, M. and CANO, J. P., 1991, Metabolism of digoxin, digoxigenin digitoxosides and digoxigenm in human hepatocytes and liver microsomes. Fundamental and Clinical Pharmacology, 5, 567-582.
15. MAHNKE, A., STROTKAMP, D., ROOS, P. H., HANSTEIN, W. G., CHABOT, G. G. and NEE, P., 1997, Expression and inducibility of cytochrome P450 3A9 (CYP3A9) and other members of the CYP3A subfamily in rat liver. Archives of Biochemistry and Biophysics, 337, 62-68.
16. NEWTON, D. J., WANG, R. W. and LU, A. Y., 1995, Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsnmes. Drug Metabolism and Disposition, 23, 154-158.
17. OLINGA, P., MEREMA, M., HOF, I. H., SLOOF, M. J., PROOST, J. H., MEIJER, D. K. and GROOTHUIS, G. M., 1998, Characterization of the uptake of rocuronium and digoxin in human hepatocytes: carrier specificity and comparison with in vivo data. Journal of Pharmacology and Experimental Therapeutics, 285, 506-510.
18. RODIN, S. M. and JOHNSON, B. F., 1988, Pharmacokinetic interactions with digoxin. Clinical Pharmacokinetics, 15, 227-244.
19. ROOS, P. H. and MAHNKE, A., 1996, Metabolite complex formation of orphenadrine with cytochrome P450. Involvement of CYP2C11 and CYP3A isozymes. Biochemical Pharmacology, 52, 73-84.
20. SCHMOLDT, A. and AHSENDORF, B., 1980, Cleavage of digoxigenin digitoxosides by rat liver microsomes. European Journal of Drug Metabolism and Pharmacokinetics, 5, 225-232.
21. SESARDIC, D., BOOBIS, A. R., MURRAY, B. P., MURRAY, S., SEGURA, J., DE LA TORRE, R. and DAVIES, D. S., 1990, Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. British Journal of Clinical Pharmacology, 29, 651-663.
22. WACHER, V. J., WU, C. Y. and BENET, L. Z., 1995, Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Molecular Carcinogenesis, 13, 129-134.
23. WANG, H. and STROBEL, H. W., 1997, Regulation of CYP3A9 gene expression by estrogen and catalytic studies using cytochrome P450 3A9 expressed in Escherichia coli. Archives of Biochemistry and Biophysics, 344, 365-372.
24. WEINHOUSE, E., KAPLANSKI, J. and GENCHIK, G., 1985, Plasma and tissue levels of digoxin in the rat following pretreatment with verapamil. Research Communications in Chemical Pathology and Pharmacology, 47, 469-472.
25. WEINHOUSE, K., KAPLANSKI, J., ZALZSTEIN, E., GENCHIK, G., COLTON, D. and NUDEL, D., 1988, Mechanisms of digoxin-amiodarone interaction in the rat. Proceedings of the Society of Experimental Biology and Medicine, 188, 96-102.
26. 3H-digoxin and its metabolites in rats. European Journal of Pharmacology, 29, 43-51.